U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Dublin, Feb. 16, 2018 -- The "Biosimilar Insulin Market Access" report has been added to ResearchAndMarkets.com's offering.
Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants Toujeo and Tresiba.
More aggressive payers are excluding branded insulin products in favor of the less expensive biosimilar, forcing switches in existing patient populations. As such, manufacturers of branded insulin products will need to offer deeper discounts to remain on payers' formularies and contracts.
Key Topics Covered:
EXECUTIVE SUMMARY
US
- Insights and strategic recommendations
- US payers are adopting a wait-and-see approach for biosimilar Basaglar
- Bibliography
FIVE MAJOR EU MARKETS
- Insights and strategic recommendations
- Uptake of biosimilar insulin varies across EU markets as the EMA does not determine interchangeability
- Physicians and payers have varying views on the interchangeability of biosimilar insulins, but see large opportunities to
- reduce costs
- Payers use biosimilars to pressure originators on pricing
- Pharmacies continue to procure both biosimilars and originators; dynamic pricing environment observed
- Patient switching requires significant discounts of at least 30%
- Given attractive discounts, payers will use a variety of market access tools to drive Basaglar's uptake
- Bibliography
METHODOLOGY
For more information about this report visit https://www.researchandmarkets.com/research/64x5p8/european_and_us?w=12
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs, Biosimilars and Biosuperiors
